News | August 27, 2014

Telik Receives $1.5 Million NCI Contract to Develop Novel Antibody-Based PET Imaging Agent for Pancreatic Cancer

August 27, 2014 — Telik Inc., a clinical stage oncology drug development company that merged with MabVax Therapeutics Inc. on July 8, announced it has received a $1.5 million contract for the Phase 2 portion of a small business innovation Research (SBIR) contract from the National Cancer Institute (NCI). The contract is intended to support a major portion of the preclinical work being conducted by MabVax, together with its collaboration partner, Memorial Sloan-Kettering Cancer Center (MSKCC) to develop a novel positron emission tomography (PET) imaging agent for the detection and assessment of pancreatic cancer.

In August 2014, MabVax Therapeutics, the wholly owned subsidiary and primary business unit of Telik, and MSKCC completed the Phase 1 of the SBIR contract by successfully demonstrating the feasibility of the project, enabling the follow-on contract award. The research contract accrues to Telik as a result of the July 2014 merger with MabVax.

J. David Hansen, CEO of Telik, commented, "Receiving the $1.5 million grant for the second phase of the NCI's research contract to develop a PET imaging agent for pancreatic cancer solidifies the preeminent position that the antibody discovery and development program developed by MabVax plays in the post-merger company. Given the inadequacy of early diagnostic screening techniques combined with typical late-stage diagnosis, pancreatic cancer is the fourth most common cause of cancer-related death in the United States. As such, new diagnostic tools specific to pancreatic cancer have the potential to address the clear need for earlier detection, as well as improving treatment regiments utilizing targeted therapies. Our radiolabeled 5B1 antibody represents the only human-derived agent in development specifically aimed at improving imaging in pancreatic cancer."

The carbohydrate antigen sialyl-Lewisa (sLea) is expressed on pancreatic colon and stomach cancers cells at high levels where it is used as a tumor marker and presents an attractive molecular target. sLea facilitates tumor adhesion and extravasation that are key events for tumor metastasis, and thus presents a marker for the very cells that cause cancer recurrence. Increased sLea expression on tumors is correlated with poor clinical outcome. MabVax Therapeutics has generated fully human monoclonal antibodies against sLea with unusual high affinity for this carbohydrate ligand. MabVax discovered the 5B1 anti-sLea antibody from a patient who was vaccinated with a sLea anti-cancer vaccine that is licensed to MabVax Therapeutics from MSKCC.

For more information: www.telik.com

Related Content

News | Business | September 19, 2017
September 19, 2017 — Invicro LLC, a provider of imaging services and software for research and drug development, anno
ScImage and Invia Partnership Announced
News | PACS | September 19, 2017
ScImage Inc. and Invia Imaging Solutions recently announced formation of a joint partnership at the American Society of...
Toshiba Highlights Latest CT Advancements at RSNA 2017
News | Computed Tomography (CT) | September 18, 2017
Toshiba Medical announced that it will display several new enhancements to its existing computed tomography (CT)...
Philips Launches CardioMD IV Cardiac SPECT Solution at ASNC 2017
Technology | SPECT Imaging | September 15, 2017
September 15, 2017 — Philips highlighted its newest solution for...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017
News | PET-CT | September 13, 2017
September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the FALC
FDG-PET/CT Predicts Melanoma Patients' Response to Immune Checkpoint Inhibitor Therapy
News | PET-CT | September 07, 2017
September 7, 2017 — Advanced melanoma has a poor prognosis, but immune checkpoint inhibitor therapy can be effective
German Team Optimizing Therapy Planning for Cancers of the Liver
News | Interventional Radiology | August 29, 2017
Radioembolization is a therapy method used for liver tumors that are uncurable with surgery or chemotherapy. Thorough...
Sponsored Content | Videos | Nuclear Imaging | August 24, 2017
Prem Soman, M.D., director of nuclear cardiology at the Heart and Vascular Institute, University of Pittsburgh, and p
Overlay Init